The present disclosure relates to an expression vector that carries a polynucleotide coding for a coagulation factor VIII mutant and has increased protein expression and a pharmaceutical composition containing the expression vector for preventing or treating hemorrhagic disease or hemorrhage.
The factor VIII mutant of the present disclosure is derived by deleting a part of the B-domain (residues 784-1667) and a part of the a3 region (residues 1668-1671) in factor VIII and, as a result, an expression vector carrying a polynucleotide coding for the factor VIII mutant has remarkably increased protein expression.